This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
18 Apr 2011

GSK To Shed Non-core OTC Products

GSK will divest non-core OTC brands for its Consumer Healthcare business around a portfolio of priority brands and emerging markets.

GSK plans to divest non-core OTC brands in an effort to focus on its Consumer Healthcare business around a portfolio of priority brands and emerging markets. The company's focus will be on three categories: Oral Health, Wellness/OTC and Nutrition, with brands such as Sensodyne, Panadol and Horlicks.
 
The products to be divested are primarily sold in Europe and the U.S.. They include analgesics such as Solpadeine, BC and Goody’s, vitamin and supplement product Abtei, feminine hygiene treatment Lactacyd, and alli for weight management. These products accounted for approximately 10% or $807 million of GSK’s total Consumer Healthcare sales in 2010. The company hopes to divest the products by late 2011.

The company also plans to sell it

Related News

  • News Swiss pharma industry warns US tariffs could harm global patient care

    The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.

  • News Understanding the Benefits and Advances of Cleanroom Technology

    In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?

  • News From Pharma to Table? Direct-to-consumer pharma sales and price cuts ramp up in US

    The pharmaceutical industry is witnessing a seismic shift as major companies embrace direct-to-consumer sales models and announce significant price reductions across the United States, responding to mounting pressure from the Trump administration to ta...
  • News A Day in the Life of a Director of Business Development

    In this Day in the Life of interview, Thomas Hauser, Director of Business Development at Tjoapack. Thomas has spent nearly 30 years in the pharmaceutical industry and describes how he still finds curiosity and excitement in the bigger picture of global...
  • News Women in Pharma: Our hopes for 2025 and beyond

    Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the...
  • News CPHI Milan 2024 - From the Floor

    Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at...
  • News The BIOSECURE Act: implications for the pharma supply chain

    On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin...
  • News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing

    The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective.